Fig. 1From: Targeted therapy monitoring of BRAF-V600-mutant Erdheim-Chester disease by fast quantitative whole-body bone CZT-tomoscintigraphiesMaximal intensity projection images of QWBT and FDG PET displayed with adapted SUV scaling (respectively 0 to 13 (Bahloul et al. 2021) and 0 to 5), (A) before and (B) after 5 months of α-interferon treatment followed by 3 months of BRAF inhibitors therapyBack to article page